Back to top
more

Geron (GERN)

(Delayed Data from NSDQ)

$3.69 USD

3.69
8,202,867

-0.04 (-1.07%)

Updated Apr 19, 2024 04:00 PM ET

After-Market: $3.70 +0.01 (0.27%) 5:04 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More

Geron Corporation (GERN) and Crinetics Pharmaceuticals (CRNX) gain on positive regulatory and study updates.

Company News for Mar 18, 2024

Companies In The Article Are: GERN, AAPL, JBL and UBER

Geron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up

Geron's (GERN) pipeline candidate, imetelstat, gets FDA Committee backing for the treatment of transfusion-dependent (TD) anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes.

Implied Volatility Surging for Geron (GERN) Stock Options

Investors need to pay close attention to Geron (GERN) stock based on the movements in the options market lately.

Geron (GERN) Upgraded to Buy: Here's Why

Geron (GERN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Kodiak Sciences Inc. (KOD) Up 43.6% Since Last Earnings Report: Can It Continue?

Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Techne (TECH) Q1 Earnings and Revenues Miss Estimates

Techne (TECH) delivered earnings and revenue surprises of -6.82% and 4.44%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Geron (GERN) Reports Q2 Loss, Lags Revenue Estimates

Geron (GERN) delivered earnings and revenue surprises of -12.50% and 79.29%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Biogen Inc. (BIIB) Tops Q2 Earnings and Revenue Estimates

Biogen Inc. (BIIB) delivered earnings and revenue surprises of 6.63% and 3.32%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Company News for May 12, 2023

Companies in The News Are: CYBR,GERN,TPR,DDS

Geron (GERN) Reports Q1 Loss, Misses Revenue Estimates

Geron (GERN) delivered earnings and revenue surprises of 22.22% and 85%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ITeos Therapeutics, Inc. (ITOS) Reports Q1 Loss, Misses Revenue Estimates

iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 55.56% and 8.73%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Seer, Inc. (SEER) Reports Q1 Loss, Tops Revenue Estimates

Seer, Inc. (SEER) delivered earnings and revenue surprises of -2.70% and 1.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Cytokinetics (CYTK) Reports Q1 Loss, Tops Revenue Estimates

Cytokinetics (CYTK) delivered earnings and revenue surprises of -11.29% and 163.60%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Why Is Bluebird (BLUE) Up 17.2% Since Last Earnings Report?

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Kodiak Sciences Inc. (KOD) Down 26.3% Since Last Earnings Report?

Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Geron (GERN) Dips More Than Broader Markets: What You Should Know

Geron (GERN) closed the most recent trading day at $2.30, moving -1.71% from the previous trading session.

Geron (GERN) Reports Q4 Loss, Misses Revenue Estimates

Geron (GERN) delivered earnings and revenue surprises of 9.09% and 11.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Protagonist (PTGX) Up on Positive Results From FRONTIER Study

Protagonist (PTGX) gains as the phase II study, conducted by Janssen, achieves its primary goal.

Intercept (ICPT) Q4 Earnings Beat, Ocaliva Sales Increase

Intercept (ICPT) posts a narrower loss in Q4 due to higher revenues.

Amicus (FOLD) Q4 Earnings Miss, Galafold Sales Beat Estimates

Amicus (FOLD) posts a wider-than-expected fourth-quarter loss but strong sales of its solely marketed drug Galafold drive the top line.

Xenon Pharmaceuticals (XENE) Reports Q4 Loss, Lags Revenue Estimates

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 1.72% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

FATE's Q4 Loss Narrower Than Expected, Pipeline in Focus

FATE reports a narrower loss and higher collaboration revenues for the fourth quarter.

Geron (GERN) Outpaces Stock Market Gains: What You Should Know

Geron (GERN) closed the most recent trading day at $2.74, moving +1.48% from the previous trading session.